Shopping Cart
Remove All
Your shopping cart is currently empty
ReACp53 acetate
😃Good
Catalog No. TP1427L
ReACp53 acetate could inhibit p53 amyloid formation and rescue p53 function in cancer cell lines.
ReACp53 acetate
😃Good
Purity: 99.55%
Catalog No. TP1427L
ReACp53 acetate could inhibit p53 amyloid formation and rescue p53 function in cancer cell lines.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $39 | - | In Stock | |
| 5 mg | $112 | - | In Stock | |
| 10 mg | $165 | - | In Stock | |
| 25 mg | $275 | - | In Stock | |
| 50 mg | $392 | - | In Stock | |
| 100 mg | $533 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.55%
Appearance:Solid
Color:White
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | ReACp53 acetate could inhibit p53 amyloid formation and rescue p53 function in cancer cell lines. |
| In vitro | ReACp53 acetate penetrates into HGSOC primary cancer cells and converts mutant p53 from a punctate state into soluble WT-like p53. ReACp53 acetate also induces cancer cell death, cell cycle arrest and results in p53 degradation. ReACp53 acetate specifically affects cell viability and proliferation of cancer cells bearing mutant p53 but not wild type when grown as organoids[1]. |
| In vivo | Only mutant p53-bearing tumors in the ReACp53 acetate-treated mice cohorts are 80-90% smaller in weight than the control cohort, confirming the ability of ReACp53 acetate to limit tumor proliferation and shrink tumors. A significant reduction of Ki67 positive cells is evident in ReACp53 acetate-treated OVCAR3 xenografts, indicative of a reduced proliferative index. Similar results are observed in the minimal residual disease model. In the paradigm, administration of ReACp53 acetate results in a significant increase in p21 and MDM2 transcription in OVCAR3 but not MCF7 xenografts. A significantly increased population is also found in G0/G1 phase, supporting proliferative arrest upon ReACp53 acetate administration in vivo[1]. |
| Molecular Weight | 2677.18 |
| Formula | C110H210N52O26 |
| Smiles | CC[C@@H]([C@H](NC([C@@H]1CCCN1C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](N)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)CCC(O)=O)=O)CC(C)C)=O)[C@H](O)C)=O)[C@H](CC)C)=O)CCCNC(N)=N)=O)[C@H](O)C)=O)CC(C)C)=O)C.CC(O)=O |
| Relative Density. | no data available |
| Sequence | H-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Pro-Ile-Leu-Thr-Arg-Ile-Thr-Leu-Glu-OH |
| Sequence Short | RRRRRRRRRRPILTRITLE |
| Storage | store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||
| Solubility Information | H2O: 9 mg/mL (3.36 mM), Sonication is recommended.  | ||||||||||
Solution Preparation Table | |||||||||||
H2O
| |||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy ReACp53 acetate | purchase ReACp53 acetate | ReACp53 acetate cost | order ReACp53 acetate | ReACp53 acetate chemical structure | ReACp53 acetate in vivo | ReACp53 acetate in vitro | ReACp53 acetate formula | ReACp53 acetate molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.